U.S. Online Retail and Ecommerce Stock News

If you are looking at Freeport-McMoRan and wondering whether the current price really reflects its value, this article will walk through what the numbers are actually saying. The stock last closed at US$60.67, with total returns of 0.7% over 7 days, 7.3% over 30 days, 16.8% year to date, 60.9% over 1 year, 49.3% over 3 years and 108.1% over 5 years. This helps frame the context for any valuation work you do today. Recent news around Freeport-McMoRan has kept attention on the stock, as...

The Opendoor Technologies Inc. ( NASDAQ:OPEN ) share price has fared very poorly over the last month, falling by a...

Summit Therapeutics (NasdaqGM:SMMT) had its Biologics License Application for ivonescimab, in combination with chemotherapy, accepted by the US FDA for EGFR mutated advanced non squamous non small cell lung cancer after TKI therapy. The company is running several late stage clinical trials, and recent international Phase III results support expanding ivonescimab development beyond lung cancer. Ivonescimab is also being studied in colorectal cancer, reflecting broader pipeline ambitions...

Earlier this week, Expedia Group reported a strong third-quarter earnings beat with record revenue, robust B2B growth and revealed plans to acquire activities platform Tiqets, while also expanding its relationship with Affirm as the exclusive Buy Now, Pay Later provider across key US brands such as Expedia, Hotels.com and Vrbo. Together, the Tiqets acquisition and Affirm partnership highlight Expedia’s push to broaden its full-trip offerings and introduce more flexible payment options across...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Primis...

Why Radware’s new AI security launch matters for shareholders Radware (RDWR) has pushed further into AI security with its Agentic AI Protection Solution, a product aimed at tackling risks tied to AI agents, prompt attacks, tool abuse, and sensitive data exposure. The launch builds on Radware’s work around threats like the recently identified ZombieAgent vulnerability and follows the earlier LLM Firewall release. Together, these developments give investors fresh context for thinking about how...

The New York Times (NYSE:NYT) reported quarterly and annual revenue that came in ahead of prior expectations, driven by digital subscriptions and advertising. The company highlighted strong contribution from its digital products, including news, games, and other subscription offerings. Management announced a higher quarterly dividend, indicating an updated capital return approach for shareholders. The publisher also outlined increased investment in video journalism and new digital content...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

Readers hoping to buy Arrow Financial Corporation ( NASDAQ:AROW ) for its dividend will need to make their move...

Atlassian (TEAM) has just posted Q2 2026 results with revenue of US$1.6b and a basic EPS loss of US$0.16, alongside trailing twelve month revenue of US$5.8b and a basic EPS loss of US$0.72 that keeps the company in the red on a full year view. The company has seen quarterly revenue move from US$1.3b in Q2 2025 to US$1.6b in Q2 2026, while quarterly basic EPS over the same periods shifted from a loss of US$0.15 to a loss of US$0.16. This sets up this release as another checkpoint on how...

If you are wondering whether Diebold Nixdorf at US$71.81 is priced attractively or asking too much for its prospects, this overview offers a clear look at what the current share price might imply. The stock has posted returns of 4.1% over the past week, 6.5% over the last 30 days and 12.3% year to date, with a 61.2% return over the past year that may have changed how some investors view its risk and reward profile. Recent company news has focused on Diebold Nixdorf's role in providing...

Intellia Therapeutics (NTLA) is back in focus after the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran in hereditary transthyretin amyloidosis with polyneuropathy, allowing enrollment to resume. See our latest analysis for Intellia Therapeutics. The FDA decision lands after a volatile stretch, with a 30 day share price return of 18.30% and a 90 day share price return of 26.21%. However, a 3 year total shareholder return of a 69.28% decline shows how...

JD.com (NasdaqGS:JD) is reportedly weighing its first offshore yuan dim sum bond, a potential funding move that sits alongside recent efforts in global logistics, international partnerships, and JD MALL expansion within China. See our latest analysis for JD.com. At a share price of $28.07, JD.com has a 1-day share price return of 2.75%. Its 1-year total shareholder return of 28.10% and 5-year total shareholder return of 68.92% point to fading longer term momentum as investors weigh funding...

Infinity Natural Resources, Inc. ( NYSE:INR ) shares have continued their recent momentum with a 26% gain in the last...

VeriSign reports 28 consecutive years of 100% domain resolution uptime. The company records its highest level of new domain registrations to date. VeriSign introduces new services focused on online security and stability. VeriSign, trading under NasdaqGS:VRSN, is drawing attention as it pairs a long running record of 100% domain resolution uptime with record high new domain registrations. The stock last closed at $224.17, with a 1 year return of 2.1% and a 5 year return of 11.7%. This...

Simulations Plus, Inc. ( NASDAQ:SLP ) shareholders won't be pleased to see that the share price has had a very rough...

Embrace Home Loans recently announced an agreement with Amalgamated Bank under which Embrace will originate and service residential mortgages for the bank’s customers on a tailored platform. The arrangement allows Amalgamated Bank to broaden its mortgage offering without building its own full-scale origination infrastructure, while still keeping customer relationships at the center of the process. Next, we’ll examine how outsourcing mortgage origination to Embrace Home Loans could influence...

Why RenaissanceRe’s latest earnings are drawing investor attention RenaissanceRe Holdings (RNR) has come into focus after reporting fourth quarter and full year 2025 results, alongside sizable share repurchases, that sharply contrast with the prior year, particularly on net income and earnings per share. See our latest analysis for RenaissanceRe Holdings. RenaissanceRe’s latest earnings and extensive buybacks appear to sit behind a 10.03% 1 month share price return and a 10.40% year to date...

Health Canada previously granted market authorization for Yorvipath (palopegteriparatide injection), Ascendis Pharma’s parathyroid hormone replacement therapy for adults with chronic hypoparathyroidism, with Pendopharm handling distribution in Canada. This approval adds another international market for Yorvipath and underscores ongoing efforts to secure public and private reimbursement to support patient access. Next, we’ll examine how this Canadian authorization for Yorvipath shapes...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Unfortunately for some shareholders, the Microvast Holdings, Inc. ( NASDAQ:MVST ) share price has dived 28% in the last...

Nextpower overview and recent performance snapshot Nextpower (NXT) has drawn fresh attention after a strong recent run in its share price, with the stock showing double digit returns over the past month and over the past three months. For investors, that move is now being weighed against the company’s current fundamentals, including revenue of US$3,603.2m, net income of US$592.1m and a value score of 3. See our latest analysis for Nextpower. With the share price at US$121.37 and a 30 day...

If you are wondering whether Azenta's current share price reflects its true worth, you are not alone. This article is built to help you connect the recent share moves with what the underlying valuation is saying. The stock closed at US$28.72, with returns of a 26.1% decline over 7 days, 24.3% decline over 30 days, 14.0% decline year to date, 45.1% decline over 1 year, 35.9% decline over 3 years and 68.3% decline over 5 years. These figures may change how investors think about both risk and...

Why Elanco Animal Health is on investors’ radar today Elanco Animal Health (ELAN) has drawn attention after recent performance data showed a 3.7% one day move, alongside gains over the past week, month and past 3 months, prompting investors to reassess the stock. See our latest analysis for Elanco Animal Health. With the share price at US$25.20 and a 1 year total shareholder return of 118.75%, recent 1 day and 90 day share price gains suggest momentum has been building rather than fading. If...